Neurotech Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial

The South Korean biotech company, Neurotech Pharmaceuticals, has begun a Phase I safety trial of AAD-2004 in healthy volunteers. The dual functioning drug was developed for its anti-oxidant and anti-inflammatory properties for the treatment of ALS and other neurodegenerative indications.

Click here to read more.

Share this: